Gils A, Knockaert I, Declerck P J
Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Belgium.
Biochemistry. 1996 Jun 11;35(23):7474-81. doi: 10.1021/bi960079d.
Plasminogen activator inhibitor-1 (PAI-1) is a unique member of the serpin superfamily. In the present study, we have evaluated the effect of substitution, with a proline, at positions P5, P7, P14, P15, or P16, on the conformational flexibility and functional properties of PAI-1. These mutants (PAI-1-P5, IIe-->Pro at P5; PAI-1-P7, Ala-->Pro at P7; PAI-1-P14, Thr-->Pro at P14; PAI-1-P15, Gly-->Pro at P15; PAI-1-P16, Ser-->Pro at P16) were purified and fully characterized. WtPAI-1 had a specific activity of 68 +/- 10% (mean +/- SD, n = 6) whereas PAI-1-P5, PAI-1-P7, and PAI-1-P16 had specific activities of 34 +/- 9.3%, 42 +/- 10%, and 36 +/- 11%, respectively. PAI-1-P14 and PAI-1-P15 did not exhibit significant inhibitory activity. Conformational analysis revealed that wtPAI-1 preparations contained 12 +/- 2.0% substrate, whereas PAI-1-P5, PAI-1-P7, and PAI-1-P16 were characterized with a significantly (p < 0.001) increased substrate behavior (i.e., 43 +/- 6.1%, 42 +/- 1.5% and 22 +/- 1.7%, respectively). The inactive variants PAI-1-P14 and PAI-1-P15 behaved exclusively as substrates toward various serine proteinases. Heat denaturation studies revealed that cleavage of any noninhibitory substrate form of PAI-1 resulted in an insertion of the NH2-terminal side of the reactive site loop. Incubation with plasmin showed the presence of a unique plasmin cleavage site (Lys191-Ser192) exclusively present in all latent forms studied. We conclude that (a) the entire P5 to P16 region in PAI-1 plays an important role in the functional and conformational properties of PAI-1; (b) the substrate behavior of serpins is not associated with a lack of insertion of the reactive site loop; (c) the identification of a plasmin cleavage site in latent PAI-1 may provide new insights in the mechanisms for the inactivation of storage pools of PAI-1.
纤溶酶原激活物抑制剂-1(PAI-1)是丝氨酸蛋白酶抑制剂超家族中的独特成员。在本研究中,我们评估了在PAI-1的P5、P7、P14、P15或P16位点用脯氨酸进行取代对其构象灵活性和功能特性的影响。对这些突变体(PAI-1-P5,P5位点异亮氨酸突变为脯氨酸;PAI-1-P7,P7位点丙氨酸突变为脯氨酸;PAI-1-P14,P14位点苏氨酸突变为脯氨酸;PAI-1-P15,P15位点甘氨酸突变为脯氨酸;PAI-1-P16,P16位点丝氨酸突变为脯氨酸)进行了纯化和全面表征。野生型PAI-1的比活性为68±10%(平均值±标准差,n = 6),而PAI-1-P5、PAI-1-P7和PAI-1-P16的比活性分别为34±9.3%、42±10%和36±11%。PAI-1-P14和PAI-1-P15未表现出显著的抑制活性。构象分析表明,野生型PAI-1制剂含有12±2.0%的底物形式,而PAI-1-P5、PAI-1-P7和PAI-1-P16的底物行为显著增加(p < 0.001)(即分别为43±6.1%、42±1.5%和22±1.7%)。无活性变体PAI-1-P14和PAI-1-P15对各种丝氨酸蛋白酶仅表现为底物。热变性研究表明,PAI-1任何非抑制性底物形式的裂解都会导致反应位点环的NH2末端侧插入。与纤溶酶孵育显示存在一个独特的纤溶酶裂解位点(Lys191-Ser192),该位点仅存在于所有研究的潜伏形式中。我们得出结论:(a)PAI-1中整个P5至P16区域在PAI-1的功能和构象特性中起重要作用;(b)丝氨酸蛋白酶抑制剂的底物行为与反应位点环未插入无关;(c)潜伏型PAI-1中纤溶酶裂解位点的鉴定可能为PAI-1储存池失活机制提供新的见解。